Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pretherapeutic prognostic factors for survival under chemoimmunotherapy/immunotherapy of advanced NSCLC patients.

European journal of cancer (Oxford, England : 1990) - 2 May 2026

Judickiene Julija, Metzenmacher Martin, Zaun Gregor, Wiesweg Marcel, Meschke Dorothea E, Guberina Nika, Oezkan Filiz, Hense Jörg, Schuler Martin, Theegarten Dirk, Bolükbas Servet, Stuschke Martin, Eberhardt Wilfried E E

Abstract excerpt

BACKGROUND: Checkpoint inhibitor therapy with PD-1/PD-L1-antibodies has significant benefits in non-small-cell lung cancer treatment even in advanced stage IVA/B. While PD-L1 expression in tumor is a weak but relevant predictor of treatment response, impact and interaction of potential prognostic factors like ECOG status, LDH-levels, CRP-levels, and genetic mutations remain so far undefined. This study aims to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to L-Lactate Dehydrogenase
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to C-Reactive Protein

Share to Carcinoma, Non-Small-Cell Lung

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Kelch-Like ECH-Associated Protein 1

Share to Progression-Free Survival

Source

Identifiers

PMID: 41780180
DOI: 10.1016/j.ejca.2026.116600

Genes

CRP
KEAP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Pretherapeutic prognostic factors for survival under chemoimmunotherapy/immunotherapy of advanced NSCLC patients.PMID 41780180Read ↗

Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Semantic proximity Read ↗

Real-world survival outcomes to first-line chemoimmunotherapy and biomarker analysis in extensive-stage small-cell lung cancerSemantic proximity Read ↗

Validation of molecular and immunological factors with predictive importance in lung cancer.Semantic proximity Read ↗

Prognostic significance of the peripheral blood CD4/CD8 ratio in lung cancer patients: A meta-analysisSemantic proximity Read ↗

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.Semantic proximity Read ↗

High Lymphocyte Population-related Predictive Factors for a Long-term Response in Non-small Cell Lung Cancer Patients Treated with Pemetrexed: A Retrospective Observational StudySemantic proximity Read ↗

[Checkpoint inhibitors in the decision-making algorithm of advanced non-small-cell lung cancer.]Semantic proximity Read ↗

PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.Semantic proximity Read ↗

Identifying predictive biomarkers of CIMAvaxEGF success in Non–Small Cell Lung Cancer Patients.Semantic proximity Read ↗

Biological prognostic and predictive factors in lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.